Marinus Pharmaceuticals (NASDAQ:MRNS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report sent to investors on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the company. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. Oppenheimer upgraded shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a report on Monday, September 23rd. Truist Financial lowered shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Finally, HC Wainwright reissued a “neutral” rating and set a $2.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Nine equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of MRNS opened at $0.26 on Thursday. The company has a 50-day simple moving average of $0.69 and a two-hundred day simple moving average of $1.16. The firm has a market capitalization of $14.50 million, a PE ratio of -0.11 and a beta of 1.25. Marinus Pharmaceuticals has a one year low of $0.25 and a one year high of $11.26.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MRNS. Hussman Strategic Advisors Inc. raised its holdings in Marinus Pharmaceuticals by 14.3% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 10,500 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Marinus Pharmaceuticals during the second quarter valued at $28,000. SG Americas Securities LLC bought a new stake in Marinus Pharmaceuticals in the 2nd quarter worth about $34,000. Finally, Values First Advisors Inc. raised its position in Marinus Pharmaceuticals by 501.8% in the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 52,257 shares during the last quarter. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.